In the Diabetes Prevention Program (DPP) clinical trial and its long-term follow-up study; but among the persons who lost at least 5% of their body weight during the first year; long-term maintenance of weight loss was more likely if they had been assigned; to treatment with metformin than with placebo or lifestyle intervention. Being older and losing a greater amount of weight in the first year; but were the most consistent predictors of lasting weight loss. Findings from a cohort study are published in Annals of Internal Medicine.
The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin; intensive lifestyle intervention (ILS), or placebo. Its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. Weight loss plays a central role in efforts to prevent or delay type 2 diabetes. As such, identifying good predictors of long-term weight loss could lead to improved weight management.
Long-term weight loss across all groups
The DPP was a randomized controlled trial that compared weight loss and diabetes prevention with metformin, intensive lifestyle intervention (ILS), or placebo among more than 3,000 participants with prediabetes, and its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. The DPP/DPPOS is the largest and longest-running study of metformin for prevention of diabetes.
After the first year, twice as many participants in the ILS group versus the metformin group lost at least 5 percent of their body weight. However, those who were assigning to the metformin group had greater success; at maintaining their weight loss between years 6 and 15, while patients were still being following. The researchers noted that greater weight loss at one year predicted long-term weight loss across all groups.
Weight loss with lifestyle interventions
Early weight loss was also important with regard to diabetes incidence. The researchers found that cumulative diabetes incidence rates over 15 years were lower among those who lost at least 5% of their weight in the first year. According to the study authors, future research should focus on whether metformin could be a useful intervention for weight loss maintenance after initial weight loss with lifestyle interventions, antiobesity drugs or devices, or bariatric surgery.
Post hoc analysis; examination of non-randomized subsets of randomized groups after year 1. Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance.